Form 4: NewAmsterdam Pharma CFO Plans Option Exercise, Share Sale

NewAmsterdam Pharma CFO Mayur Ian Somaiya has filed a Form 4 detailing pre-planned stock option exercises and subsequent sales of ordinary shares scheduled for January 2026 under a Rule 10b5-1 plan.

Summary

• Mayur Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma Co N.V. (NAMS), has filed a Form 4 reporting pre-planned transactions involving the exercise of stock options and subsequent sale of ordinary shares, scheduled for January 2026.
• On January 20, 2026, Somaiya is scheduled to exercise options to acquire 60,216 ordinary shares at an exercise price of $9.26 per share.
• On the same day, he is scheduled to sell a total of 60,220 ordinary shares across multiple transactions at average prices ranging from $30.64 to $32.38 per share.
• On January 21, 2026, Somaiya is scheduled to exercise options to acquire 39,784 ordinary shares at an exercise price of $9.26 per share.
• Also on January 21, 2026, he is scheduled to sell a total of 39,784 ordinary shares across multiple transactions at average prices ranging from $33.25 to $33.80 per share.
• All sales are planned to be conducted pursuant to a Rule 10b5-1 trading plan, established to comply with insider trading regulations.
• Following these scheduled transactions, Somaiya will beneficially own 58,382 ordinary shares directly and 662,814 derivative securities (options).

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing under a 10b5-1 plan, which is a standard practice for executives. It doesn't inherently signal positive or negative company performance, but rather personal financial planning.

Positives

• The transactions are pre-planned and scheduled for January 2026, executed under a Rule 10b5-1 trading plan, which indicates adherence to insider trading regulations and reduces concerns about opportunistic timing.
• The exercise price of the options ($9.26) is significantly lower than the planned sale prices (ranging from $30.64 to $33.80), indicating a substantial unrealized gain being realized by the CFO.

Negatives

• The CFO is scheduled to sell a significant number of shares (100,000 total) which could be perceived as a reduction in direct equity exposure, although this is offset by the exercise of options.

Future Outlook

The filing details pre-planned transactions set to occur in January 2026, indicating the CFO's long-term financial planning under a Rule 10b5-1 plan. The vesting schedule for the options suggests continued service is expected through the vesting period.

Management Comments

• This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. Such transactions, especially when executed under a 10b5-1 plan, are common across all industries, including pharmaceuticals, as executives manage their equity compensation and personal finances while adhering to insider trading regulations. It does not provide specific insights into NewAmsterdam Pharma's operational performance or industry trends.

Comparison to Industry Standards

• Insider transactions under Rule 10b5-1 plans are standard practice for executives in publicly traded companies across all sectors, including biotechnology and pharmaceuticals.
• The structure of exercising options and selling shares is a common method for executives to realize value from their equity compensation, manage tax liabilities, and diversify personal holdings.
• There are no specific comparable companies or projects mentioned in this transactional filing.

Stakeholder Impact

• Shareholders: The planned sale of shares by a CFO, even under a 10b5-1 plan, could be viewed by some as a slight reduction in direct equity exposure, though the simultaneous exercise of options mitigates this. The overall impact is likely minimal given the pre-planned nature and routine disclosure.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The reported transactions are scheduled to occur on January 20 and 21, 2026.
• The remaining options will continue to vest in equal monthly installments for three years after the one-year anniversary of the vesting start date (November 1, 2023), subject to the CFO's continued service.

Key Dates

Recommendation

This Form 4 filing details pre-planned insider transactions (option exercises and sales) by the CFO under a Rule 10b5-1 plan. Such transactions are routine for executives managing their equity compensation and personal finances and do not typically reflect a change in the company's fundamental outlook or performance. The significant spread between the exercise price and planned sale price indicates the CFO is realizing gains from previously granted options. Given the nature of the filing, it provides no new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

NewAmsterdam Pharma, NAMS, Form 4, Insider Trading, Stock Options, Rule 10b5-1, CFO, Equity Sales, Beneficial Ownership, Pharmaceuticals